These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

174 related articles for article (PubMed ID: 28585885)

  • 1. Validity of Danish Breast Cancer Group (DBCG) registry data used in the predictors of breast cancer recurrence (ProBeCaRe) premenopausal breast cancer cohort study.
    Cronin-Fenton DP; Kjærsgaard A; Ahern TP; Mele M; Ewertz M; Hamilton-Dutoit S; Christiansen PM; Ejlertsen B; Sørensen HT; Lash TL; Silliman RA
    Acta Oncol; 2017 Sep; 56(9):1155-1160. PubMed ID: 28585885
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cohort Profile: the Predictors of Breast Cancer Recurrence (ProBe CaRE) Premenopausal Breast Cancer Cohort Study in Denmark.
    Collin LJ; Cronin-Fenton DP; Ahern TP; Christiansen PM; Damkier P; Ejlertsen B; Hamilton-Dutoit S; Kjærsgaard A; Silliman RA; Sørensen HT; Lash TL
    BMJ Open; 2018 Aug; 8(7):e021805. PubMed ID: 30068618
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Clinicopathological factors predicting early and late distant recurrence in estrogen receptor-positive, HER2-negative breast cancer.
    Yamashita H; Ogiya A; Shien T; Horimoto Y; Masuda N; Inao T; Osako T; Takahashi M; Endo Y; Hosoda M; Ishida N; Horii R; Yamazaki K; Miyoshi Y; Yasojima H; Tomioka N;
    Breast Cancer; 2016 Nov; 23(6):830-843. PubMed ID: 26467036
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Estrogen receptor, Progesterone receptor, HER2 status and Ki67 index and responsiveness to adjuvant tamoxifen in postmenopausal high-risk breast cancer patients enrolled in the DBCG 77C trial.
    Knoop AS; Lænkholm AV; Jensen MB; Nielsen KV; Andersen J; Nielsen D; Ejlertsen B;
    Eur J Cancer; 2014 May; 50(8):1412-21. PubMed ID: 24675287
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Mortality rates among early-stage hormone receptor-positive breast cancer patients: a population-based cohort study in Denmark.
    Christiansen P; Bjerre K; Ejlertsen B; Jensen MB; Rasmussen BB; Lænkholm AV; Kroman N; Ewertz M; Offersen B; Toftdahl DB; Møller S; Mouridsen HT;
    J Natl Cancer Inst; 2011 Sep; 103(18):1363-72. PubMed ID: 21881042
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Adjuvant chemotherapy in early breast cancer.
    Ejlertsen B
    Dan Med J; 2016 May; 63(5):. PubMed ID: 27127018
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Breast cancer recurrence, bone metastases, and visceral metastases in women with stage II and III breast cancer in Denmark.
    Cronin-Fenton D; Kjærsgaard A; Nørgaard M; Amelio J; Liede A; Hernandez RK; Sørensen HT
    Breast Cancer Res Treat; 2018 Jan; 167(2):517-528. PubMed ID: 28948396
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A validated algorithm for register-based identification of patients with recurrence of breast cancer-Based on Danish Breast Cancer Group (DBCG) data.
    Aagaard Rasmussen L; Jensen H; Flytkjær Virgilsen L; Jellesmark Thorsen LB; Vrou Offersen B; Vedsted P
    Cancer Epidemiol; 2019 Apr; 59():129-134. PubMed ID: 30743224
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Forty years of landmark trials undertaken by the Danish Breast Cancer Cooperative Group (DBCG) nationwide or in international collaboration.
    Ejlertsen B; Offersen BV; Overgaard J; Christiansen P; Jensen MB; Kroman N; Knoop AS; Mouridsen H
    Acta Oncol; 2018 Jan; 57(1):3-12. PubMed ID: 29205077
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Relationship between the prognostic and predictive value of the intrinsic subtypes and a validated gene profile predictive of loco-regional control and benefit from post-mastectomy radiotherapy in patients with high-risk breast cancer.
    Tramm T; Kyndi M; Myhre S; Nord S; Alsner J; Sørensen FB; Sørlie T; Overgaard J
    Acta Oncol; 2014 Oct; 53(10):1337-46. PubMed ID: 24957550
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Factors associated with concordant estrogen receptor expression at diagnosis and centralized re-assay in a Danish population-based breast cancer study.
    Cronin-Fenton DP; Hellberg Y; Lauridsen KL; Ahern TP; Garne JP; Rosenberg C; Silliman RA; Sørensen HT; Lash TL; Hamilton-Dutoit S
    Acta Oncol; 2012 Feb; 51(2):254-61. PubMed ID: 22129357
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Health-related quality of life in early breast cancer.
    Groenvold M
    Dan Med Bull; 2010 Sep; 57(9):B4184. PubMed ID: 20816024
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Optimal systemic therapy for premenopausal women with hormone receptor-positive breast cancer.
    Jankowitz RC; McGuire KP; Davidson NE
    Breast; 2013 Aug; 22 Suppl 2():S165-70. PubMed ID: 24074781
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Failure pattern and survival after breast conserving therapy. Long-term results of the Danish Breast Cancer Group (DBCG) 89 TM cohort.
    Lyngholm CD; Laurberg T; Alsner J; Damsgaard TE; Overgaard J; Christiansen PM
    Acta Oncol; 2016 Aug; 55(8):983-92. PubMed ID: 27120011
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Adjuvant endocrine treatment of postmenopausal patients with breast cancer with high risk of recurrence. 5. Results from the DBCG (Danish Breast Cancer Cooperative Group) 77C randomized trial].
    Rose C; Andersen JA; Andersen KW; Axelsson CK; Blichert-Toft M; Dombernowsky P; Hansen M; Krag C; Mouridsen HT; Overgaard M
    Ugeskr Laeger; 1991 Aug; 153(33):2283-7. PubMed ID: 1781047
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Study of failure pattern among high-risk breast cancer patients with or without postmastectomy radiotherapy in addition to adjuvant systemic therapy: long-term results from the Danish Breast Cancer Cooperative Group DBCG 82 b and c randomized studies.
    ; Nielsen HM; Overgaard M; Grau C; Jensen AR; Overgaard J
    J Clin Oncol; 2006 May; 24(15):2268-75. PubMed ID: 16618947
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Adjuvant endocrine therapy in pre- versus postmenopausal patients with steroid hormone receptor-positive breast cancer: results from a large population-based cohort of a cancer registry.
    Inwald EC; Koller M; Klinkhammer-Schalke M; Zeman F; Hofstädter F; Lindberg P; Gerstenhauer M; Schüler S; Treeck O; Ortmann O
    J Cancer Res Clin Oncol; 2015 Dec; 141(12):2229-40. PubMed ID: 26253629
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prognostic factors of early distant recurrence in hormone receptor-positive, postmenopausal breast cancer patients receiving adjuvant tamoxifen therapy: results of a retrospective analysis.
    Debled M; MacGrogan G; Brouste V; Mathoulin-Pelissier S; Durand M; Mauriac L
    Cancer; 2007 Jun; 109(11):2197-204. PubMed ID: 17450590
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Recurrence pattern and prognosis in low-risk breast cancer patients--data from the DBCG 89-A programme.
    Christiansen P; Al-Suliman N; Bjerre K; Møller S;
    Acta Oncol; 2008; 47(4):691-703. PubMed ID: 18465337
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The clinical database and implementation of treatment guidelines by the Danish Breast Cancer Cooperative Group in 2007-2016.
    Jensen MB; Laenkholm AV; Offersen BV; Christiansen P; Kroman N; Mouridsen HT; Ejlertsen B
    Acta Oncol; 2018 Jan; 57(1):13-18. PubMed ID: 29202621
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.